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ABSTRACT 
Objective: The current study is an attempt to screen for the in vitro clot lysis and proteolytic activity of aqueous extract of Leucas aspera leaves.  
Methods: Thrombolytic activity and protease activity of the crude enzyme obtained by ammonium sulfate precipitation and dialysis were assayed 
using blood clot and casein as substrates respectively. Native PAGE and gel documentation studies were performed to calculate the molecular 
weight of the enzyme.  
Results: In the study, 40% salt fractioned crude enzyme sample exhibited significant thrombolytic and caseinolytic activity. Further dose-
dependent increased activity was observed with the maximum lytic activity of 52.11±1.04 % at 1 mg/ml of the sample when compared to the 
reference drug streptokinase (71.39±0.32%). Also, 68.72±0.62 U/hr of caseinolytic activity was observed for 1 mg/ml of the sample fraction.  
Conclusion: The study highlights and validates the efficacy of Leucas aspera leaves extract for thrombolytic and proteolytic actions. Enzyme with an 
approximate molecular weight, 19.89 KDa could be responsible for the significant lytic activity.  
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INTRODUCTION 
Blood clot (thrombus) developed in the circulatory system due to the 
failure of homeostasis causes vascular blockage and while recovering 
leads to serious consequences in atherothrombotic diseases [1-3]. 
Thromboembolic disorders such as myocardial infarction, 
cerebrovascular thrombosis, pulmonary embolism, and venous 
thrombolism are life-threatening for human beings [4]. Thrombolytics 
are used to dissolve the fibrin of blood clots, which are potentially life-
threatening, especially those in the arteries of the heart and lungs. It is 
also used against the clot formed in shunts during kidney dialysis and 
multiple pulmonary emboli. Commonly used thrombolytic agents are 
Alteplase, Anistreplase, Streptokinase, Urokinase, and tissue 
plasminogen activator (TPA) to dissolve clots [5].  
All available thrombolytic agents still have significant shortcomings, 
including the need for large doses to be maximally effective, limited 
fibrin specificity. Though streptokinase and urokinase are widely 
used due to their lower cost, as compared to other thrombolytic 
drugs, these are dangerous because they might cause serious 
bleeding complications along with reocclusion and reinfarction [6]. 
Because of the shortcomings of the available thrombolytic drugs, 
attempts are underway to develop improved recombinant variants 
of these drugs [7-9]. Day by day the context, concept, and methods of 
the use of natural products in the treatment of humans have 
undergone remarkable changes. Such changes occurred since 
natural medicine or traditional medicine made a revolutionary 
come-back with renewed strength and vigor to play a more 
significant role in the management of human health [10]. 
Some plants or plant parts showing thrombolytic activity have also 
been reported. For example, plant extracts of Ageratum conyzoides L, 
Clausena suffruticosa, Leea indica and peel extract of Punica granatum 
showed a significant percentage of clot lysis compared to reference 
drug streptokinase [11-13]. Leucas aspera, belonging to the family of 
Labiatae, is a common aromatic herb. Traditionally, the whole plant is 
used for analgesic, antipyretic, antirheumatic, anti-inflammatory, and 
antibacterial treatment. Its anti-inflammatory activity has been shown 
in animal models through prostaglandin inhibition [14-17]. The 
current study aims at determining the thrombolytic and proteolytic 
activities of Leucas aspera leaves extract. 
MATERIALS AND METHODS 
Chemicals and reagents 
Streptokinase and trypsin (RM612) were purchased from Sigma Aldrich, 
St Louis, MO, USA. Casein, Bovine Serum Albumin, TEMED and PAGE 
chemicals from HI–MEDIA, Mumbai, India. All the chemicals and 
reagents used were of analytical grade. Fresh human blood samples 
were collected from healthy volunteers after obtaining their consent. 
Plant material 
Fresh leaves of Leucas aspera were collected during the year 2017–
18 from Saranda chiria forest, Paschimi Singhbhum district of 
Jharkhand, India and taxonomically authenticated by Prof. Hari 
Shankar, Plant taxonomist, Jharkhand Biodiversity Board, Ranchi, 
India. The sample specimen was submitted to the Botanical survey 
of India, Kolkata (Herbarium voucher number–86206).  
Preparation of extract 
Leucas aspera leaves sample was cleaned, shade dried, pulverized, 
and stored in an airtight container. 
50 gm of leaf powder was homogenized with distilled water using 
mortar and pestle. The extract was filtered and centrifuged at 5000 
RPM for 15 min. The supernatant was subjected to protein 
precipitation for 40% ammonium sulphate fractionation. After 
ammonium sulphate precipitation, the sample was subjected to 
centrifugation for 10 min at 10,000g. The precipitated pellet was 
dissolved in 10 mmol phosphate buffer and dialyzed against the 
same buffer to remove ammonium sulphate. Protein concentration 
of the fraction was measured at 540 nm using Biuret reagent.  
Caseinolytic activity  
Caseinolytic activity was assayed as per the method of Murata et al. 
[18]. Briefly, 0.4 ml casein (2% in 0.2 M Tris–HCl buffer. pH 8.5) was 
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incubated with different concentrations (250‑1000 μg) of 40% 
fraction and trypsin at 37 °C separately for 2 h. The reaction was 
stopped by adding 1.5 ml of the 0.44M TCA and allowed to stand for 30 
min followed by centrifugation at 1500g for 15 min. An aliquot (1 ml) 
of the supernatant was mixed with 2.5 ml of the 0.4M sodium 
carbonate and 0.5 ml of FC reagent (1:2) followed by reading 
absorbance at 660 nm. One unit of enzyme activity was defined as the 
amount of the enzyme required to increase in absorbance of 0.01 at 
660 nm/h at 37 °C. Enzyme activity was expressed as U/h at 37 °C. 
Thrombolytic activity 
In vitro thrombolytic activity in terms of clot lysis was carried out. 
Venous blood drawn from healthy volunteers was transferred in 
different pre-weighed sterile microcentrifuge tubes (500 μl/tube) and 
incubated at 37 °C for 45 min. After clot formation, serum was 
completely removed and each tube having clot was again weighed to 
determine the clot weight (clot weight = weight of clot containing 
tube-weight of the tube alone). Each micro-centrifuge tube containing 
the clot was properly labeled and various concentrations of the crude 
enzyme were added to the tubes (20-100 μg). Distilled water and 
streptokinase were added separately to the tubes containing the clot 
to serve as a negative control and positive control respectively. All the 
tubes were then incubated at 37 °C for 90 min and observed for clot 
lysis. Fluid obtained after incubation was removed and tubes were 
again weighed to observe the difference in weight after clot disruption. 
The difference obtained in the weight before and after clot lysis was 
expressed as the percentage of clot lysis. 
 X 100 
Electrophoresis 
Native PAGE (12%) was carried out for 40% dialyzed fraction and 
the bands were visualized by staining with Coomassie Brilliant Blue 
R250. Gel imaging and documentation were done using the Bio-Rad 
Gel Doc EZ system.  
Statistical analysis  
The analysis was done using Microsoft excel. All the experiments 
were conducted in triplicates. One-way ANOVA and post hoc tests 
were conducted and P values less than 0.05 were considered as 
significantly different. Values were represented as mean±SEM.  
RESULTS AND DISCUSSION 
Proteases constitute one of the most important groups of industrial 
enzymes, accounting for about 60% of the total enzyme market. 
Recent years have envisaged a surge in enzyme market growth due 
to diverse key factors including cost-effectiveness and productivity. 
Plant proteases have been implicated in the design and synthesis of 
therapeutic agents [19]. Herein we report on the potent protease 
and clot lysis activities of the enzyme from L. aspera leaves extract. 
40% dialyzed fraction contained 1.6 mg/ml of crude protein. Native 
PAGE under non-reducing conditions revealed a dense single banding 
for the crude enzyme of 40% dialysis fraction (DF) from L. aspera (fig. 
1a). Proteolytic activity of the crude enzyme from 40% dialysis 
fraction was examined using casein as a substrate. DF exhibited 
potential caseinolytic activity when 2 % of casein was used as a 
substrate. The activity was progressively increased with an increase in 
the concentration of the enzyme fraction. The protein concentration 
ranging from 250μg/ml to 1000μg/ml exhibited a mean activity of 
19.63±0.19 U/hr to 68.72±0.62 U/hr respectively (fig. 2). Trypsin and 
distilled water (DW) used as a positive and negative control showed 
activities of 84.2±1.18 U/hr and 2.56±0.09 U/hr respectively (table 1). 
Furthermore, purification and characterization of protease(s) are in 
progress to categorize the protease for two varied classes viz., cysteine 
proteases or serine proteases. 
 
 
Fig. 1: Native PAGE of 40% DF A–sample, B–marker protein
 
 
Fig. 2: Protease activity of 40% dialysed fraction, values are mean±SEM, n=3, significant at ap<0.05 
 
Thrombolytic activity 
Fibrinolytic enzymes dissolve fibrin, the main component of blood 
clots. Accumulation of fibrin in the blood vessels results in thrombosis, 
leading to myocardial infarction, and other heart diseases [20]. 
Several anticoagulants, anti-platelet, and thrombolytic medications are 
used for the treatment of thrombotic disorders. Anticoagulants 
and anti-platelet agents prevent the formation of blood clots but do 
not dissolve existing clots, whereas thrombolytic agents can dissolve a 
clot but emboli can form even after successful treatment. Thus, none of 
them provide a permanent and complete solution [21]. Thrombolytic 
drugs dissolve blood clots by activating plasminogen, which forms a 
cleaved product called plasmin. Plasmin is a proteolytic enzyme that is 
capable of breaking cross-links between fibrin molecules, thereby 
dissolving the blood clots.  
The addition of the DF with enzyme aliquots varying from 250 to 
1000μg/ml to the preformed blood clots and subsequent incubation 
for 90 min at 37 °C demonstrated a dose-dependent response with 
maximum lysis of 52.11±1.04 % (table 1). 100μl of streptokinase 
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taken as a positive control (35000 IU) showed 71 % clot lysis 
activity and distilled water used as negative control exhibited 6.04 
% of lysis action (fig. 3). Gel documentation study for the 40% DF 
resolved under nonreducing native PAGE divulged the approximate 
molecular weight of the crude enzyme as 19.89 KDa (fig. 1b) which 
is attributed to the lysis of clot releasing the fibrin monomers. 
  
 
Fig. 3: Clot lysis activity of crude enzyme from dialyzed fraction, values are mean±SEM, n=3, significant at ap<0.05 
 
Table 1: Protease and thrombolytic activities of crude enzyme 
Sample Protease activity (U/h) Thrombolytic activity (% lysis) 
DW 2.56±0.09 6.04±0.21 
Trypsin 84.20±1.18 - 
Streptokinase  - 71.39±0.32 
DF (250μg/ml)  19.63±0.19a 16.18±0.26a 
DF (500μg/ml)  36.79±0.86a 28.17±0.59a 
DF (1000μg/ml)  68.72±0.62a 52.11±1.04a 
DF–Dialyzed fraction from 40% salt precipitation, values are means±SEM, n = 3, significant at ap<0.05 
 
CONCLUSION 
In the context of the above result and discussion, it can be concluded 
that the enzyme extract of L. aspera leaves possesses significant 
protease and thrombolytic activity compared to the standard enzyme 
trypsin and streptokinase respectively. However, further studies are in 
progress to purify and characterize the enzyme from the crude 
dialyzed sample. Also cytotoxic studies have to be taken up further to 
explore the medical and pharmaceutical potentiality of the plant. 
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